Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
Results Demonstrate Safety of CVN424 and Enable Initiation of Phase 2 Study in Patients BOSTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/CNS?src=hash" target="_blank"gt;#CNSlt;/agt;–Cerevance, a clinical…